Great Point Partners LLC Acquires 285,714 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Great Point Partners LLC increased its holdings in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 10.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,906,259 shares of the company's stock after purchasing an additional 285,714 shares during the period. UroGen Pharma accounts for 9.3% of Great Point Partners LLC's investment portfolio, making the stock its biggest position. Great Point Partners LLC owned about 12.39% of UroGen Pharma worth $48,767,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Cowen AND Company LLC boosted its holdings in UroGen Pharma by 29.1% in the second quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company's stock valued at $35,229,000 after acquiring an additional 472,893 shares during the last quarter. RTW Investments LP increased its position in UroGen Pharma by 101.4% during the 4th quarter. RTW Investments LP now owns 1,726,808 shares of the company's stock worth $25,902,000 after purchasing an additional 869,344 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in UroGen Pharma in the first quarter valued at approximately $4,008,000. Superstring Capital Management LP acquired a new position in UroGen Pharma during the fourth quarter valued at approximately $3,831,000. Finally, Vanguard Group Inc. grew its stake in UroGen Pharma by 14.3% during the first quarter. Vanguard Group Inc. now owns 194,966 shares of the company's stock worth $2,924,000 after buying an additional 24,367 shares during the period. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Stock Up 0.7 %

NASDAQ URGN traded up $0.09 on Tuesday, hitting $13.06. 346,459 shares of the stock traded hands, compared to its average volume of 478,447. The company has a current ratio of 8.15, a quick ratio of 7.93 and a debt-to-equity ratio of 3.23. The stock has a 50-day moving average of $14.64 and a 200 day moving average of $14.70. UroGen Pharma Ltd. has a twelve month low of $10.60 and a twelve month high of $20.70. The company has a market capitalization of $306.31 million, a P/E ratio of -3.84 and a beta of 1.11.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to analysts' expectations of $23.69 million. As a group, analysts expect that UroGen Pharma Ltd. will post -3.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. LADENBURG THALM/SH SH increased their price target on UroGen Pharma from $48.00 to $53.50 and gave the company a "buy" rating in a report on Friday, June 14th. Oppenheimer raised their target price on UroGen Pharma from $32.00 to $40.00 and gave the company an "outperform" rating in a report on Friday, June 14th. Guggenheim initiated coverage on UroGen Pharma in a report on Thursday, August 22nd. They issued a "buy" rating and a $40.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $60.00 price objective on shares of UroGen Pharma in a research note on Wednesday, August 14th.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.